PhRMA Clinical Trial Code: Disclosure Edition
The Pharmaceutical Research and Manufacturers of America is committing its members to disclose a broader array of clinical trials as a means to defend the corporate-sponsored clinical development process against continuing charges of bias and against the erosion of public trust
You may also be interested in...
The federal clinical trials registry is growing at a 20 to 40 percent faster clip as a result of the FDA Amendments Act provision expanding the universe of trials subject to public listing requirements
The settlement includes a modest $2.5 mil. disgorgement fee. GSK is also required to advertise the clinical trial register in seven prominent peer reviewed journals.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.